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Abstract
Background: With 249,007 new leprosy patients detected globally in 2008, it remains necessary to develop new and
effective interventions to interrupt the transmission of M. leprae. We assessed the economic benefits of single dose
rifampicin (SDR) for contacts as chemoprophylactic intervention in the control of leprosy.
Methods:We conducted a single centre, double blind, cluster randomised, placebo controlled trial in northwest Bangladesh
between 2002 and 2007, including 21,711 close contacts of 1,037 patients with newly diagnosed leprosy. We gave a single
dose of rifampicin or placebo to close contacts, with follow-up for four years. The main outcome measure was the
development of clinical leprosy. We assessed the cost effectiveness by calculating the incremental cost effectiveness ratio
(ICER) between the standard multidrug therapy (MDT) program with the additional chemoprophylaxis intervention versus
the standard MDT program only. The ICER was expressed in US dollars per prevented leprosy case.
Findings: Chemoprophylaxis with SDR for preventing leprosy among contacts of leprosy patients is cost-effective at all
contact levels and thereby a cost-effective prevention strategy. In total, $6,009 incremental cost was invested and 38
incremental leprosy cases were prevented, resulting in an ICER of $158 per one additional prevented leprosy case. It was the
most cost-effective in neighbours of neighbours and social contacts (ICER $214), slightly less cost-effective in next door
neighbours (ICER $497) and least cost-effective among household contacts (ICER $856).
Conclusion: Chemoprophylaxis with single dose rifampicin given to contacts of newly diagnosed leprosy patients is a cost-
effective intervention strategy. Implementation studies are necessary to establish whether this intervention is acceptable
and feasible in other leprosy endemic areas of the world.
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Introduction
Leprosy is a chronic infectious disease, caused by the bacillus
Mycobacterium leprae, which affects the skin and peripheral nerves
leading to skin lesions, loss of sensation, and nerve damage. This in
turn can lead to secondary impairments or deformities of the eyes,
hands and feet. For treatment purposes, leprosy is classified as
either paucibacillary (PB) or multibacillary (MB) leprosy. The
standard treatment for leprosy is multidrug therapy (MDT) [1]. PB
patients are treated for 6 months with dapsone and rifampicin;
MB patients are treated for 12 months with dapsone, rifampicin
and clofazamine.
The World Health Organisation (WHO) had set a goal in the
early 1990s to eliminate leprosy as a public health problem by the
year 2000. Elimination was defined as reducing the global
prevalence of the disease to less than 1 case per 10 000 population
[2]. The WHO elimination strategy was based on increasing the
geographical coverage of MDT and patients’ accessibility to the
treatment. The expectation existed that reduction in prevalence
through expanding MDT coverage would eventually also lead to
reduction in incidence of the disease and ultimately to elimination
in terms of zero incidence of the disease. An important assumption
underlying the WHO leprosy elimination strategy was that
MDT would reduce transmission of M. leprae through a reduc-
tion of the number of contagious individuals in the community
[3]. Unfortunately, there is no convincing evidence for this
hypothesis [4].
With a total of 249 007 new patients detected globally in 2008
[5], it remains necessary to develop new and effective interventions
to interrupt the transmission of M. leprae. BCG vaccination against
tuberculosis offers some but not full protection against leprosy and
in the absence of another more specific vaccination against the
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bacillus other strategies need to be developed, such as preventive
treatment (chemoprophylaxis) of possible sub-clinically infected
people at risk of developing leprosy. Recently, the results were
published of randomised controlled trial into the effectiveness of
single dose rifampicin (SDR) in preventing leprosy in contacts of
patients [6]. It was shown that this intervention is effective at
preventing the development of leprosy at two years and that the
initial effect was maintained afterwards.
In order to assess the economic benefits of SDR as an
intervention in the control of leprosy, we performed a cost-
effectiveness analysis. We provide an overview of the direct costs of
this new chemoprophylaxis intervention and calculate the cost-
effectiveness compared to standard MDT provision only.
Methods
Study population
This study was based on the results of the prospective (sero-)
epidemiological study on contact transmission and chemoprophy-
laxis in leprosy (COLEP; ISRCTN 61223447), which was
conducted in the Rangpur and Nilphamari districts of northwest
Bangladesh between 2002 and 2007 by the Rural Health Program
(RHP) of The Leprosy Mission Bangladesh. The population of the
two districts was 4.4 million in 2002, and the number of newly
detected leprosy cases in 2002 was 1 317 [7]. Of these, 1 037
patients were included in the COLEP study; 400 with single lesion
PB leprosy, 342 with PB leprosy of 2–5 lesions, and 295 with MB
leprosy. Intake started in June 2002. Contacts were categorised
according to their physical distance to the index patient [8]. For
physical distance we defined six categories on the basis of the local
housing situation: shares a house only (R) or a house and a kitchen
(KR), shares a kitchen only (K), next-door neighbours (N1),
neighbours of the neighbours (N2), and social (S) contacts (business
contacts and colleagues staying in the same room for at least four
hours a day, five days a week).
Study design
The COLEP study was a single centre, double blind, cluster
randomised, placebo controlled trial. A complete description of the
COLEP trial is given by Moet et al. [6]. In short, at intake - that is,
after the index patient had received the second supervised dose of
MDT – all contacts of one patient received prophylactic
treatment, which included either capsules with 150 mg rifampicin
or identical placebo capsules without an active (antibiotic)
ingredient. According to bodyweight and age, each contact took
two to four capsules under direct supervision of a staff member. Of
the 1 037 patients, 517 were allocated to the intervention arm and
520 to the placebo arm of the trial. The number of contacts in the
intervention arm was 10 857 and 10 854 in the placebo arm. A
follow-up investigation took place two years after intake, starting in
June 2004, and completed in February 2006. The primary
outcome of the trial was the development of clinical leprosy.
Ethical clearance
Ethical clearance was obtained from the Ethical Review
Committee of the Bangladesh Medical Research Council in
Dhaka (ref. no. BMRC/ERC/2001–2004/799). All subjects were
informed verbally in their own language (Bangla) about the study
and invited to participate. Written consent was requested from
each adult. For children consent from a parent or guardian was
given.
Cost calculations
Cost calculations were done from the health care perspective, in
which real medical costs were calculated for the chemoprophylaxis
intervention compared to the standard MDT treatment program.
All direct medical costs of the general health program and the
related indirect costs (e.g. transport) for the period 2002–2004
were included. Real medical costs were calculated by multiplying
the volumes of health care use with the corresponding unit prices.
The calculations of the full cost of the standard MDT treatment
program and the rifampicin chemoprophylaxis were based on real
resources. If information on resource use and the full cost were
available, bottom-up calculations were performed [9]. If detailed
information about resource use and unit costs were not available,
top-down calculations were performed [10]. Prevention of
disabilities, patients’ costs and costs caused by loss of production
due to absence from work were not taken into account because no
reliable data were available. Table 1 provides an overview of the
cost calculation method and data source per cost category. All
costs were converted into unit prices in US dollars per volume,
using the exchange rates of the UN for Bangladeshi taka (BDT) in
US dollars ($) [11].
The costs of the standard MDT treatment program consisted of
the leprosy costs made by the RHP in 2004, including all program
costs such as personnel costs (salaries, allowances and staff benefits
for all administrative, financial and field staff), transportation costs,
surveys (contact and village), overhead costs (administration, repair
and maintenance, health education). All data were adjusted for the
leprosy share only of the RHP program and based on costs of 2002
and 2003 [12,13], and extrapolated to 2004 with the correspond-
ing inflation rate [11] because no reliable detailed information was
available for 2004. The treatment for leprosy was based on data of
the Novartis Foundation for Sustainable Development, which
supplies the MDT free of charge [14]. Costs of surgical
interventions were based on reconstructive surgery and corre-
sponding hospital costs of 2002. For the treatment of complica-
tions all medical intervention and hospital costs were included,
based on the annual report of the RHP. The number of patients
needing complication treatment was calculated according to the
Bangladesh Acute Nerve Damage (BAND) study [15–17].
Information from this study was necessary because no data were
available for the number of leprosy patients with complications in
the COLEP trial. The BAND study was a prospective cohort study
of 2 664 new leprosy cases from the same area and the same
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population as the COLEP study. Over a period of three years
incidence rates were calculated with the number of patients
developing the following complications: nerve function impair-
ment, type 1 and type 2 reactions, and silent neuritis. Recorded
complication rates in the BAND study were extrapolated to the
COLEP cohort. The various complications require different
treatment regimens, e.g. mild type 1 reaction requires less
corticosteroids than severe type 1 reaction. The appropriate
treatment for each complication and the associated costs were
based on the guidelines for leprosy treatment current at the time of
the study [18]. Expert clinical opinion was taken for the average
number of mild or severe reaction types. For reversal reactions
(RR or Type 1) a distribution of 50% mild and 50% severe
reactions was taken, and for erythema nodosum leprosum (ENL or
Type 2) per leprosy patient having a reaction an average of two
mild and two severe recurrences were taken, costing $ 3.41 and $
69.58 per patient involved, respectively.
The chemoprophylaxis intervention is additional to the
standard MDT treatment program. Therefore, costs for the
intervention consist of two components, the basic health care
(represented by the standard treatment) and the intervention costs.
Therefore, no extra costs for basic health care were added since
the intervention is additional to existing practice. For the cost of
chemoprophylaxis, COLEP costs were used based on the cost
statements of the COLEP Research Study 2002–2004. The
chemoprophylaxis costs were calculated bottom-up from the
COLEP data base by multiplying the cost for the mean number
of capsules ($ 0.21 for 3.5 capsules) with the number of contacts in
the intervention. Other medical costs consisted of MDT for all
newly detected leprosy patients and treatment of complications.
Cost-effectiveness analysis
Cost effectiveness of the COLEP trial was assessed by
calculating the incremental cost effectiveness ratio (ICER) between
the standard MDT program with the additional chemoprophy-
laxis intervention versus the standard MDT program only. We
chose the perspective of the program level, calculating the total
costs of the program for the standard treatment and added per
treatment arm the costs for medical treatment. The difference in
treatment costs with and without the intervention was calculated
and compared with the difference in the number of newly detected
cases among the contacts. Costs and benefits were modelled in a
decision tree [9], in which effectiveness was measured by the
number of prevented leprosy cases (Figure 1). The ICER was
expressed in US dollar per prevented leprosy case as follows:
ICER~
Total CostI{Total CostST
Leprosy CasesI{Leprosy CasesST
~
DCost
DLeprosy Cases
,
where ‘I’ denotes intervention and ‘ST’ refers to Standard
treatment. Costs and effects were discounted annually with 3.5%
[19].
Sub-group analyses were also carried out by distance group as
defined in studies of Moet et al. The ICER for a specific subgroup
was dependent on: i) the differences between the whole program
costs, ii) the differences in the number of recipients of additional
treatment and consequential costs and iii) differences in the
number of new leprosy cases found in the sub-group [6,7].
Sensitivity analysis
To evaluate the uncertainty around the ICER, sensitivity
analyses were performed by probabilistic sensitivity analysis (PSA)
drawing 500 random samples. The costs and the efficiency of the
program were deemed as deterministic but beta distributions were
assigned to the complication probabilities to model the uncertainty
around it [20]. Parameters of the beta distributions were based on
the BAND study.
Results
In total 20 032 contacts of 1037 leprosy patients remained in
the trial after 2 years (taking into account loss of follow-up of
7.7%); 10 038 in the standard treatment (placebo) arm and 9 994
in the intervention (chemoprophylaxis) arm of the trial. The
distributions of contacts over the two arms of the trial according to
the physical distance of the contact to the index patient and the
number of new leprosy cases detected in the contact groups after
two years are shown in Table 2. The overall reduction of leprosy
in the rifampicin arm of the trial compared to the standard
treatment arm was 38 cases (57%).
Table 3 shows the total costs of different cost categories in the
contact group of standard MDT treatment and of the chemopro-
phylaxis intervention. Program costs, which consisted of the costs
of personnel, transportation and overhead, were higher for the
intervention group, with around $ 4 000 due to extra personnel
and transportation requirements of the program. The medical
costs among the index patients of both groups amounted to
approximately $ 5 700, and consisted of the treatment of leprosy
with MDT and the treatment of complications. MDT treatment
totalled up to $ 4 500, whereas complications estimated to have a
burden of $ 1 180. The cost of complications consisted of costs of
surgery and the treatment of the two known reaction types in
leprosy. This was calculated as follows: unit cost of surgery was
estimated to be $ 95 with a probability of need of 4.1% in MB and
1% in PB subgroups. Altogether surgery costs summed up to $ 740
in each treatment arm. The cost of reaction type 1 was $ 8, and the
chance to develop such reaction was 31.7% and 2.5% in the MB
and PB groups, respectively. The corresponding values for type 2
reaction were $ 71, 2% and 0%. Costs of reaction type 1
Table 1. Calculation method and data source per cost
category for the full cost analysis of the standard MDT
treatment program.
Cost category
Calculation
method Data source
Program*:
Personnel Top-down Annual Reports DBLM [12,13]
Transport Top-down Annual Reports DBLM [12,13]
Overhead Top-down Annual Reports DBLM [12,13]
Medical:
Treatment of leprosy
MDT** Top-down Novartis Foundation [14]
Treatment of complications:
Reaction type 1 Bottom-up DBLM- Field guidelines [18]
Reaction type 2 Bottom-up DBLM- Field guidelines [18]
Surgical intervention*** Top-down Annual Reports DBLM [12,13]
The costs (in US$) represent actual expenditures on materials and services obtained.
*Full cost price per newly detected cases among contacts.
**Per month per patient receiving a MDT blister-pack. Based on $ 37 million
production cost and $ 3 million on transportation with a production of 32
million blister-packs, for MB 12 blister packs and for PB 6 blister packs are
needed, costs $ 15 and $ 7.50, respectively.
***Per patient involved.
doi:10.1371/journal.pntd.0000874.t001
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amounted to $ 300, whereas type 2 amounted to $ 142. Total cost
of standard treatment was estimated to be $ 132 287, whereas
chemoprophylaxis intervention needed $ 138 309 investment. The
additional cost of the intervention is thus $ 6 022.
The incremental cost effectiveness ratio (ICER) indicates the
cost effectiveness of the additional chemoprophylaxis intervention
in contacts after 2 years versus the standard MDT treatment for all
contacts together and for the three different distance groups. The
ICER is expressed in US dollars saved per one prevented leprosy
case. In total an incremental of $ 6 009 was invested and 38
incremental leprosy cases were prevented by chemoprophylaxis in
contacts on the whole program level, resulting in an ICER of $ 158
(CI: 146–171) per one additional prevented leprosy case (Table 4).
Sub-group analyses revealed that chemoprophylaxis was cost-
effective for all three contact groups. It was the most cost-effective
in neighbours of neighbours and social contacts (ICER $ 214), and
slightly less cost-effective in next door neighbours (ICER $ 497)
and least cost-effective among household contacts (ICER $ 856).
Incorporation of the probabilistic aspect of the complication part
into the model did not change the results considerably. The ICERs
spread only in a narrow range both at the whole program level
and at the sub-group level.
Discussion
Chemoprophylaxis with single dose rifampicin for preventing
leprosy among contacts is a cost-effective prevention strategy. At
program level an incremental of $ 6 009 was invested and 38
incremental leprosy cases were prevented, resulting in an ICER of
$ 158 per one additional prevented leprosy case.
This is the first report on cost-effectiveness of single dose
rifampicin as chemoprophylaxis in contacts of leprosy patients.
The analysis is based on the results of a large randomized
controlled trial in Bangladesh [6]. For the analysis, the health care
perspective was taken because indirect cost data were largely
unavailable. The health care perspective excludes indirect costs
Table 2. Number of leprosy patients arising from contacts after 2 years according to physical distance of the contacts to the index
patient, by intervention (standard treatment vs. chemoprophylaxis).
Physical distance of contact to index Standard treatment Chemoprophylaxis
Total contacts With leprosy Total contacts With leprosy
MB PB MB PB
Household contacts (KR+R) 1 660 7 11 1 642 2 11
Next door neighbours (K+N1) 2 787 2 15 2 552 2 6
Neighbours of neighbours and social contacts (N2+S) 5 591 0 32 5 800 0 8
Total 10 038 9 58 9 994 4 25
doi:10.1371/journal.pntd.0000874.t002
Figure 1. Model structure to calculate benefits (newly diagnosed leprosy patients) and costs of chemoprophylaxis with single dose
rifampicin.
doi:10.1371/journal.pntd.0000874.g001
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(patient costs), such as travel costs, loss of income due to illness and
clinic visits, and long term consequences of disability. Estimating
these costs was beyond the scope of this study, but inclusion would
have rendered the intervention even more cost-effective. Another
limitation of the study is that a static approach was taken to the
analysis, measuring the effect of the intervention after two years
only. After these two years, there was no further reduction of new
cases in the chemoprophylaxis arm of the trial compared to the
placebo arm. Because leprosy is an infectious disease, with person-
to-person transmission of M. leprae, one can expect that prevention
of primary cases (as recorded in the trial) will lead to further
prevention of secondary cases. In time, this would lead to further
cost-effectiveness of the intervention. Unfortunately, we could not
apply such a dynamic analysis approach because there is
insufficient information about the long term effects of the
intervention, including the number of secondary cases prevented
and the number of primary cases prevented after two years that
will eventually develop leprosy after a longer period of time,
beyond the 4 years observation period of the trial.
It is also important to understand that the results of the COLEP
trial reflect a comparison between the chemoprophylaxis inter-
vention and standard MDT treatment plus contact surveys at 2-
year intervals with treatment of newly diagnosed cases among
contacts. A contact survey in itself is an intervention that reduces
transmission in contact groups and thus new leprosy patients
among contacts. The provision of chemoprophylaxis to contacts
requires contact tracing, but contact tracing is not part of leprosy
control programs in many countries and doing so would increase
program costs considerably. WHO however, recognizes the
importance of contact tracing and now recommends that it is
introduced in all control programs [21]. This would then also lay a
good foundation for introducing chemoprophylaxis.
WHO reports regarding cost-effectiveness analyses recommend
using disability adjusted life years (DALY) as outcome measure for
such studies [22]. In leprosy two measures are common to express
disability: WHO grade 1 and 2 [23]. The disability weight for
grade 2 disability (visible deformity) has been determined at 0.153
[24], but no weight is available for grade 1. Of all newly detected
leprosy cases, a relatively low percentage (2–35%) have grade 2
disability [25]. In our study we chose for the number of leprosy
cases prevented as outcome, because there is little information
available about survival of patients with grade 2 disability and also
because the choice for DALY’s would have given a less favourable
result due to the low weight of leprosy disability.
There are a number of issues to take into account when relating
the outcome of this study to other countries. Firstly, the cost level
to conduct leprosy control will differ per country, due to economic
standard, budget allocated to primary health care, salaries of
health care workers, etc. In our calculation, program costs were
similar for both the standard MDT treatment and chemoprophy-
laxis intervention, but these costs will vary per country. The
treatment costs are based on real cost estimates and will vary less
between countries and programs. Therefore the actual costs will
differ, but the conclusion that the intervention is cost-effective is
Table 3. Summary of total costs in the two treatment arms (in US$).
Cost category Standard treatment
Chemoprophylaxis
Intervention Difference
1. Program 126 583 130 544 +3 961
Personnel 93 455 92 916 2539
Additional personnel - 3 389 +3 389
Transportation 7 398 7 355 243
Additional transportation - 1 303 +1 303
Overhead 25 730 25 581 2149
2. Medical 5 704 5 678 226
Treatment of leprosy 4 524 4 498 226
Treatment of complications 1 180 1 180 0
3. Intervention (SDR) 0 2 087 +2 087
Sum [1+2+3] 132 287 138 309 +6 022
doi:10.1371/journal.pntd.0000874.t003
Table 4. Incremental cost effectiveness ratio’s (ICER) per prevented leprosy case (in US$) of the chemoprophylaxis intervention for
all contacts together and for different distance categories.
Physical distance of contact to index
Average cost-
difference in US$
Difference in number of cases
detected
Average ICER per case prevented
(95% CI)*
Absolute Discounted
All contacts together $ 6 009 238 235.5 158 (146–171)
Household contacts (KR+R) $ 4 278 25 24.7 856 (762–952)
Next door neighbours (K+N1) $ 4 472 29 - 497 (444–553)
Neighbours of neighbours and social contacts (N2+S) $ 5 148 224 222.4 214 (194–234)
*ICER at 2.5% and 97.5% of the non-parametric bootstrap sample.
doi:10.1371/journal.pntd.0000874.t004
CEA Rifampicin Chemoprophylaxis Leprosy
www.plosntds.org 5 November 2010 | Volume 4 | Issue 11 | e874
very likely to remain the same. Secondly, the clinical presentation
of leprosy differs between countries and regions. Globally the
distribution is around 40% for MB and 60% for PB in newly
detected leprosy cases, but with widely varying ratios between
countries [25]. Since costs for treating PB and MB leprosy are
different, these differences are likely to affect the outcome of the
cost-effectiveness analysis. Thirdly, the percentage of newly
detected cases that are a household contact of a known leprosy
patient differs per country and is possibly determined by the
endemicity level of leprosy in a country or area. In Bangladesh, in
the high endemic area where the COLEP study was conducted,
approximately 25% of newly detected cases had a known index
case within the family, whereas in a low endemic area (Thailand)
this proportion was 62% [26]. An intervention aimed at close
(household) contacts may therefore be more cost-effective in
countries where relatively many new cases are household contacts.
But the background and implications of such differences on
effectiveness of chemoprophylaxis needs further research.
Only few articles have been published about cost-effectiveness
analyses of interventions in leprosy [27]. Most articles assess small
parts of leprosy control, such as footwear provision [28], MDT
delivery costs [29], or the economic aspects of hospitalisation
versus ambulatory care of neuritis in leprosy reactions [30]. Only
two studies provided a more general cost-effect analysis. Naik and
Ganapati included several costs in their economic evaluation, but
a limitation of the study is the lack of reference about how they
obtained their cost data [31]. Remme et al. based the cost
calculations in their study on the limited available published cost
data, program expenditure data and expert opinion, and also
provide limited insight into how they obtained certain costs and
effects [30]. Both studies do not mention well how the costs are
obtained, (e.g. real costs, bottom-up or top-down costs). Our
current article is basically one of the first structured cost-effective
analyses for leprosy presenting an overview of the costs involved
and can be used for the assessment of the costs of leprosy control in
general.
This report shows that chemoprophylaxis with single dose
rifampicin given to contacts of newly diagnosed leprosy patients is
a cost-effective intervention strategy. Implementation studies in
the field are necessary to establish whether this intervention is
acceptable and feasible in other leprosy endemic areas of the
world.
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